These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37498162)

  • 1. Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease.
    McLaughlin MM; Durstenfeld MS; Gandhi M; Greene M; Ma Y; Beatty AL; Hsue PY
    AIDS; 2023 Nov; 37(14):2179-2183. PubMed ID: 37498162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life's Essential 8 is associated with atherosclerotic cardiovascular disease but not venous thromboembolism in men: a prospective cohort study.
    Isiozor NM; Laukkanen JA; Voutilainen A; Bensenor IM; Kunutsor SK
    Ann Med; 2023 Dec; 55(1):2233894. PubMed ID: 37459575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease.
    Gallegos Aragon K; Ray G; Conklin J; Stever E; Marquez C; Magallanes A; Anderson J; Jakeman B
    Am J Health Syst Pharm; 2022 Nov; 79(22):2026-2031. PubMed ID: 35976174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women.
    Borja-Hart N; Graff JC; Nolan VG; Wang J; Cooper-DeHoff RM; Ancheta IB
    J Clin Pharm Ther; 2019 Aug; 44(4):632-639. PubMed ID: 30963623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease.
    Erqou S; Papaila A; Halladay C; Ge A; Liu MA; Jiang L; Lally M; Menon A; Shah NR; Miech E; Virani SS; Zullo AR; Shireman TI; Longenecker CT; Ross D; Sullivan JL; Wu WC; Rudolph JL
    Am Heart J; 2022 Jul; 249():12-22. PubMed ID: 35318028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
    Delabays B; de La Harpe R; Vollenweider P; Fournier S; Müller O; Strambo D; Graham I; Visseren FLJ; Nanchen D; Marques-Vidal P; Vaucher J
    Eur J Prev Cardiol; 2023 Nov; 30(17):1856-1864. PubMed ID: 37290056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network.
    Saeed A; Zhu J; Thoma F; Marroquin O; Aiyer A; Agarwala A; Virani SS; Gulati M; Lee JS; Reis S; Saba S; Ballantyne C; Mulukutla S
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007485. PubMed ID: 34455825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Landscape of ASCVD Risk Among Patients With HIV.
    Malvestutto C
    J Fam Pract; 2022 Jul; 71(6 Suppl):S58-S62. PubMed ID: 35960946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
    Mufarreh A; Shah AJ; Vaccarino V; Kulshreshtha A
    JAMA Netw Open; 2023 Jan; 6(1):e2251156. PubMed ID: 36656581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
    Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
    PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
    Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
    JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life's Essential 8 and the risk of cardiovascular disease death and all-cause mortality in Finnish men.
    Isiozor NM; Kunutsor SK; Voutilainen A; Laukkanen JA
    Eur J Prev Cardiol; 2023 Jun; 30(8):658-667. PubMed ID: 36753230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease.
    Wong ND; Zhao Y; Xiang P; Coll B; López JAG
    Am J Cardiol; 2020 Dec; 137():7-11. PubMed ID: 32991855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
    Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE
    HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system.
    Sidebottom AC; Vacquier MC; Jensen JC; Bradley SM; Knickelbine T; Strauss C; Miedema MD
    Clin Cardiol; 2020 Jun; 43(6):560-567. PubMed ID: 32104922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
    Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA
    JAMA Cardiol; 2017 Jan; 2(1):47-54. PubMed ID: 27829091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
    Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
    Bellows BK; Olsen CJ; Voelker J; Wander C
    J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.